Gilead Sciences Initiates Enrollment in Phase II Clinical Trial Of Cicletanine Hydrochloride To Treat PAH - international news
Tuesday, Gilead Sciences Inc. (GILD: News) said it has initiated enrolling patients in a Phase II clinical trial of cicletanine hydrochloride, an oral agent in development for the treatment of pulmonary arterial hypertension.
The cicletanine Phase II study is a randomized, double blind, placebo-controlled, multicenter, dose-ranging study designed to evaluate the safety, efficacy and tolerability of cicletanine.